© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Thyroid Cancers | Clinical
Multikinase Inhibitor Options Abound for Patients With RET-Mutant Medullary Thyroid Cancer
November 25, 2020
During a Targeted Oncology Case Based Peer Perspectives event, Marcia S. Brose, MD, PhD, discussed options for a 58-year-old patient with RET-mutant medullary thyroid cancer.
Task Force Recommends Active Surveillance for Many Low-Risk Papillary Thyroid Microcarcinoma Patients
November 19, 2020
Active surveillance can be a safe and appropriate management strategy for patients with T1aN0M0 low-risk papillary thyroid microcarcinoma, though the decision to use the strategy requires multidisciplinary teams and patient input, according to a new report.
Real-World Date Confirm Vandetanib and Cabozantinib Are Effective 1L/2L Treatments for Medullary Thyroid Cancer
November 19, 2020
For the majority of patients with medullary thyroid cancer, vandetanib and cabozantinib are both effective treatment options, according to results from a retrospective analysis.
Larotrectinib Shows Efficacy in TRK Fusion Thyroid Cancer
November 19, 2020
Maria E. Cabanillas, MD, discusses the pooled results of 2 larotrectinib trials for patients with advanced or metastatic TRK fusion-positive thyroid cancer.
Objective Responses Observed in Rare Thyroid Tumors With Dual Checkpoint Blockade
November 12, 2020
The combination of ipilimumab with nivolumab induced an objective response rate of 12% as treatment of patients with thyroid cancer.
Real-World Data Support Use of Multikinase Inhibitors in Differentiated Thyroid Cancer
October 20, 2020
In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the findings for the global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.
TRK Fusions Help to Fulfill Unmet Need in Thyroid Cancer Treatment Landscape
October 16, 2020
Maria E. Cabanillas, MD, discusses the treatment landscape for patients with thyroid cancers harboring a TRK fusion.
ESMO Data Show Benefit of Approved Thyroid Cancer Regimens in Select Patients
October 14, 2020
Across subsets of patients with thyroid cancer, an interesting collection of research was shared with oncologists during the 2020 European Society of Medical Oncology Virtual Congress, demonstrating improvement in outcomes for patients with thyroid cancers with newer and established approved regimens.
Patient-Reported Outcomes Confirm Tolerability of Selpercatinib in RET-Driven Thyroid Cancer
October 12, 2020
In an interview with Targeted Oncology, Lori J. Wirth, MD, discussed the findings from an analysis of the patient-reported outcomes observed in the LIBRETTO-001 study of selpercatinib in patients with RET-driven thyroid cancers.
A 73-Year-Old Woman With Differentiated Thyroid Cancer
September 25, 2020
Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.